… erlotinib in the first-line setting of advanced NSCLC evaluated prospectively if increasing the
dose of erlotinib … our understanding of the impact of erlotinib on our patients were explored. …

… Erlotinib, an inhibitor of tyrosine … on erlotinib use in squamous NSCLC are limited. This
observational study aimed at evaluating the efficacy and safety of second-line erlotinib in patients …

… first-line chemotherapy, the first-line treatment with erlotinib was … that a strategy of first-line
erlotinib would be cost-effective was … of using erlotinib first to treat white patients with EGFR-…

… To our knowledge, this is the first comparative analysis of the efficacy of second-line
docetaxel and erlotinib treatment in patients with advanced NSCLC. The efficacy of …

… of patients included in the QoL analyses in the erlotinib (90%) and chemotherapy (75%)
groups. The erlotinib patients were … with patients in the chemotherapy group. This imbalance in …

… study of Japanese NSCLC patients was 11.8 months with first-line erlotinib treatment, which
… , confirming that erlotinib can provide a good PFS benefit in this subgroup. Erlotinib was …

… Erlotinib might have also been recommended as third-line in the 2009 ASCO … in patients
who received erlotinib as third-line compared with those who received erlotinib as second-line […

… patient. In this article, the authors analyzed data of erlotinib in NSCLC, focusing on its role
in front-line … and seventeen patients received erlotinib as first- (113 patients) or second/third-…

… with unknown EGFR mutations, as well as in 80% of patients … second-line or third-line
chemotherapeutic agent for patients … as first-line or maintenance treatment for patients with EGFR …

… Demographics of third line docetaxel are identical to second line EGFRTKI as all patients
that received second line EGFRTKI received subsequent docetaxel, as a result of the …